Monopar Therapeutics — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Monopar Therapeutics filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Mar 28, 2024 |
| FY2019 | Dec 31, 2019 | $0 | Mar 27, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 26, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.72M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($15.59M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.40M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($10.52M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.10M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($6.30M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($4.22M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.23M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($16.55M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($1.19M) | Mar 26, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.70M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($16.16M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($8.83M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($10.54M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($9.13M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($6.51M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($4.32M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($3.33M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($16.60M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($1.19M) | Mar 26, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.90M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $13.01M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $5.60M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.59M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.49M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $4.07M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.97M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.77M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $935.3K | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $280.4K | Mar 26, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.20M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($6.40M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($7.86M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.23M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($7.32M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($4.66M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($3.02M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($2.68M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($2.63M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($1.19M) | Mar 26, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.72M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $60.29M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $7.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.23M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $20.52M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $16.87M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $13.35M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.32M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $9.93M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $2.90M | Mar 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.89M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.25M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.58M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.18M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $724.2K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $399.6K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $311.9K | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $64.5K | Mar 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.83M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $55.04M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $5.59M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $10.09M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $18.94M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $15.69M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $12.63M | Mar 24, 2022 |
| FY2020 | Dec 31, 2018 | $6.92M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $9.62M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $2.83M | Feb 26, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($89.51M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($75.79M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($60.21M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($51.80M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($41.29M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($32.19M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($25.88M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($21.66M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($18.43M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($1.87M) | Mar 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.83M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $45.82M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $7.27M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.19M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $20.30M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $16.74M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $13.21M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $6.89M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.98M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $2.07M | Mar 26, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.69M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 6.10M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 2.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 12.95M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 12.60M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 11.45M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 10.59M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 9.29M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 9.29M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 26, 2018 |